The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. The metric has seen a significant loss of -20.57% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -26.84%. Over the past 30 days, the price of MREO has fallen by 19.83%. And in the last five days, it has surged by 13.01%.
Mereo Biopharma Group Plc ADR experienced a somewhat shaky performance in the stock market.
52-week price history of MREO Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Mereo Biopharma Group Plc ADR’s current trading price is -44.62% away from its 52-week high, while its distance from the 52-week low is 76.51%. The stock’s price range during this time has been between $1.58 and $5.02. The trading volume for the Healthcare sector company’s shares reached about 1.0 million for the day, which was lower than the average daily volume of 1.38 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Mereo Biopharma Group Plc ADR (MREO) has experienced a quarterly rise of 11.20% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 442.02M and boasts a workforce of 36 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
MREO’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for MREO stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.00.
